The active-manager-led accumulation (Walleye Capital doubling) combined with insider buying and a strong Q2 beat suggests continued momentum. Monitor for further insider buying and Q3 2026 revenue guidance updates; the 92% analyst bullish consensus may narrow as the company approaches profitability. The 45-day 13F lag means positions may have been adjusted since quarter-end.
Executive Summary
Four institutional investors accumulated $2.9M in Biodesix (BDSX) during Q2 2026, led by Walleye Capital doubling its position to $1.7M and Geode adding 35% to $1.5M. The cluster follows a strong Q2 earnings beat (revenue +34% YoY, EPS beat by 21.4%) filed 9 days ago, and is corroborated by $1.0M in open-market insider buying. The sole seller, Morgan Stanley, exited a trivial position. The active-manager-led buying combined with insider confluence signals conviction in the diagnostic testing growth story, though the company remains unprofitable with a net loss of $7.3M.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.4M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Walleye Capital | DOUBLED | +586.8% | $1.7M | $1.5M |
| Geode | ADD | +35.3% | $1.5M | $801.0K |
| BlackRock | ADD | +75.9% | $970.0K | $615.0K |
| Fidelity | DOUBLED | +9400% | $2.0K | $2.0K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | NEAR_EXIT | -99.8% | $470.0K | -$468.3K |
Key Facts
- 4 institutional buyers added $2.9M in Q2 2026, led by Walleye Capital (+$1.5M to $1.7M) and Geode (+$801K to $1.5M)
- Morgan Stanley was the sole seller, exiting 99.8% of its position for a trivial $1K remaining
- Cluster follows Q2 2026 earnings beat (revenue +34% YoY, EPS beat by 21.4%) filed 9 days prior
- 1 insider open-market buyer added $1.0M in the last 30 days, corroborating institutional conviction
- Diagnostic Testing revenue grew 42% YoY to $25.4M on 38% volume growth; gross margins expanded to 82%
- Company remains unprofitable with a net loss of $7.3M in Q2 2026
Financial Impact
4 institutions accumulated $2.9M in new positions while 1 seller reduced holdings by $468K, net institutional inflow of ~$2.4M
Risk Factors
- 45-day 13F reporting lag — positions may have been unwound since June 30
- Company remains unprofitable with a net loss of $7.3M; path to profitability is uncertain
- Morgan Stanley's near-full exit, though small, signals potential concern from one major institution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-BDSX-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $23.87 | awaiting T+20 | — | — |
Oct 19, 2026 7d ago | Press Release | $23.40 | awaiting T+20 | — | — |
Aug 15, 2026 10w ago | Institutional Cluster | $23.25 $27.70 | ▲ +19.14% | ▲ +21.12% | — |
Aug 13, 2026 10w ago | Insider Buy | $24.00 $27.40 | ▲ +14.17% | ▲ +16.16% | — |
Aug 12, 2026 10w ago | Insider Buy | $23.79 $26.97 | ▲ +13.35% | ▲ +15.09% | — |
Aug 5, 2026 11w ago | 8-K | $22.10 $26.48 | ▲ +19.80% | ▲ +19.20% | — |
Jun 1, 2026 21w ago | EFFECT | $15.27 $22.55 | ▲ +47.68% | ▲ +48.97% | — |
May 4, 2026 25w ago | Press Release | $14.94 $15.44 | ▲ +3.35% | ▼ −1.61% | — |
Apr 20, 2026 27w ago | Press Release | $13.17 $14.25 | ▲ +8.20% | ▲ +4.00% | — |
Mar 20, 2026 31w ago | Press Release | $14.88 $13.17 | ▼ −11.46% | ▼ −20.78% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers